share_log

金斯瑞生物科技：截至二零二四年六月三十日止六個月之未經審核合併中期業績公告

GENSCRIPT BIO: ANNOUNCEMENT OF UNAUDITED CONSOLIDATED INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024

Hong Kong Stock Exchange ·  Aug 9 22:53
Summary by Futu AI
金斯瑞生物科技於二零二四年六月三十日止六個月公佈未經審核合併中期業績，收益強勁增長43.5%，達561.4百萬美元。非細胞療法業務收益略降0.2%，細胞療法業務收益顯著增加156.0%。毛利同比增加75.4%，達307.0百萬美元。虧損收窄至215.6百萬美元，經調整淨虧損減少至69.0百萬美元。公司未宣派中期股息，並無購買、出售或贖回任何上市證券。董事會對未來業務發展保持信心，感謝股東及員工的支持。
金斯瑞生物科技於二零二四年六月三十日止六個月公佈未經審核合併中期業績，收益強勁增長43.5%，達561.4百萬美元。非細胞療法業務收益略降0.2%，細胞療法業務收益顯著增加156.0%。毛利同比增加75.4%，達307.0百萬美元。虧損收窄至215.6百萬美元，經調整淨虧損減少至69.0百萬美元。公司未宣派中期股息，並無購買、出售或贖回任何上市證券。董事會對未來業務發展保持信心，感謝股東及員工的支持。
GenScript Bio announced its unaudited consolidated interim results for the six months ended on June 30, 2024, with strong revenue growth of 43.5% to USD 561.4 million. Non-cell therapy business revenue slightly decreased by 0.2%, while cell therapy business revenue significantly increased by 156.0%. Gross profit increased by 75.4% YoY to USD 307.0 million. The loss narrowed to USD 215.6 million, and the adjusted net loss reduced to USD 69.0 million. The company has not declared a mid-year dividend, nor purchased, sold, or redeemed any listed securities. The board of directors remains confident in the future development of the business and appreciates the support of shareholders and employees.
GenScript Bio announced its unaudited consolidated interim results for the six months ended on June 30, 2024, with strong revenue growth of 43.5% to USD 561.4 million. Non-cell therapy business revenue slightly decreased by 0.2%, while cell therapy business revenue significantly increased by 156.0%. Gross profit increased by 75.4% YoY to USD 307.0 million. The loss narrowed to USD 215.6 million, and the adjusted net loss reduced to USD 69.0 million. The company has not declared a mid-year dividend, nor purchased, sold, or redeemed any listed securities. The board of directors remains confident in the future development of the business and appreciates the support of shareholders and employees.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.